These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 11093372)

  • 1. Feasibility of detecting hypoxia in experimental mouse tumours with 18F-fluorinated tracers and positron emission tomography--a study evaluating [18F]Fluoro-2-deoxy-D-glucose.
    Bentzen L; Keiding S; Horsman MR; Falborg L; Hansen SB; Overgaard J
    Acta Oncol; 2000; 39(5):629-37. PubMed ID: 11093372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of hypoxia in experimental mice tumours by [18F]fluoromisonidazole PET and pO2 electrode measurements. Influence of tumour volume and carbogen breathing.
    Bentzen L; Keiding S; Horsman MR; Grönroos T; Hansen SB; Overgaard J
    Acta Oncol; 2002; 41(3):304-12. PubMed ID: 12195751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma.
    Grönroos T; Bentzen L; Marjamäki P; Murata R; Horsman MR; Keiding S; Eskola O; Haaparanta M; Minn H; Solin O
    Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):513-20. PubMed ID: 14722675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of intratumoral heterogeneity in oxygenation status on FMISO PET, autoradiography, and electrode Po2 measurements in murine tumors.
    Sørensen M; Horsman MR; Cumming P; Munk OL; Keiding S
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):854-61. PubMed ID: 15936570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Voxel based comparison and texture analysis of 18F-FDG and 18F-FMISO PET of patients with head-and-neck cancer.
    Kroenke M; Hirata K; Gafita A; Watanabe S; Okamoto S; Magota K; Shiga T; Kuge Y; Tamaki N
    PLoS One; 2019; 14(2):e0213111. PubMed ID: 30818360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility of imaging photodynamic injury to tumours by high-resolution positron emission tomography.
    Moore JV; Waller ML; Zhao S; Dodd NJ; Acton PD; Jeavons AP; Hastings DL
    Eur J Nucl Med; 1998 Sep; 25(9):1248-54. PubMed ID: 9724373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study.
    Gagel B; Reinartz P; Demirel C; Kaiser HJ; Zimny M; Piroth M; Pinkawa M; Stanzel S; Asadpour B; Hamacher K; Coenen HH; Buell U; Eble MJ
    BMC Cancer; 2006 Mar; 6():51. PubMed ID: 16515707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography.
    Lawrentschuk N; Poon AM; Foo SS; Putra LG; Murone C; Davis ID; Bolton DM; Scott AM
    BJU Int; 2005 Sep; 96(4):540-6. PubMed ID: 16104907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG--a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer.
    Zimny M; Gagel B; DiMartino E; Hamacher K; Coenen HH; Westhofen M; Eble M; Buell U; Reinartz P
    Eur J Nucl Med Mol Imaging; 2006 Dec; 33(12):1426-31. PubMed ID: 16841141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introducing fluorine-18 fluoromisonidazole positron emission tomography for the localisation and quantification of pig liver hypoxia.
    Piert M; Machulla H; Becker G; Stahlschmidt A; Patt M; Aldinger P; Dissmann PD; Fischer H; Bares R; Becker HD; Lauchart W
    Eur J Nucl Med; 1999 Feb; 26(2):95-109. PubMed ID: 9933343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia.
    Rasey JS; Hofstrand PD; Chin LK; Tewson TJ
    J Nucl Med; 1999 Jun; 40(6):1072-9. PubMed ID: 10452326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma.
    Yeh SH; Liu RS; Wu LC; Yang DJ; Yen SH; Chang CW; Yu TW; Chou KL; Chen KY
    Eur J Nucl Med; 1996 Oct; 23(10):1378-83. PubMed ID: 8781144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
    Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
    Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model.
    Dubois L; Landuyt W; Cloetens L; Bol A; Bormans G; Haustermans K; Labar D; Nuyts J; Grégoire V; Mortelmans L
    Eur J Nucl Med Mol Imaging; 2009 Feb; 36(2):209-18. PubMed ID: 18690432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiosensitizing effect of irisquinone on glioma through the downregulation of HIF-1α evaluated by 18F-FDG and 18F-FMISO PET/CT.
    Wang H; Zhang Y; Yu W; Zhao X; Xue Y; Xu H
    Nucl Med Commun; 2016 Jul; 37(7):705-14. PubMed ID: 26963468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between tumor oxygenation and 18F-fluoromisonidazole PET data simulated based on microvessel images.
    Mönnich D; Troost EG; Kaanders JH; Oyen WJ; Alber M; Zips D; Thorwarth D
    Acta Oncol; 2013 Oct; 52(7):1308-13. PubMed ID: 23984808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma.
    Thézé B; Bernards N; Beynel A; Bouet S; Kuhnast B; Buvat I; Tavitian B; Boisgard R
    BMC Cancer; 2015 Jul; 15():534. PubMed ID: 26198000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients.
    Thorwarth D; Eschmann SM; Holzner F; Paulsen F; Alber M
    Radiother Oncol; 2006 Aug; 80(2):151-6. PubMed ID: 16920211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the distribution of fluorine-18 fluoromisonidazole, deoxyglucose and methionine in tumour tissue.
    Kubota K; Tada M; Yamada S; Hori K; Saito S; Iwata R; Sato K; Fukuda H; Ido T
    Eur J Nucl Med; 1999 Jul; 26(7):750-7. PubMed ID: 10398823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic fate of 18F-FDG in mice bearing either SCCVII squamous cell carcinoma or C3H mammary carcinoma.
    Kaarstad K; Bender D; Bentzen L; Munk OL; Keiding S
    J Nucl Med; 2002 Jul; 43(7):940-7. PubMed ID: 12097467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.